enstilar húðfroða 50 míkróg/0,5 mg/g
leo pharma a/s* - calcipotriolum inn; betamethasonum díprópíónat - húðfroða - 50 míkróg/0,5 mg/g
opzelura
incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - aðrar húðsjúkdómar - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
panodil junior endaþarmsstíll 125 mg
haleon denmark aps - paracetamolum inn - endaþarmsstíll - 125 mg
doloproct endaþarmsstíll 1 mg + 40 mg
karo pharma ab* - fluocortolonum pívalat; lidocainum hýdróklóríð - endaþarmsstíll - 1 mg + 40 mg
asacol endaþarmsstíll 500 mg
tillotts pharma ab - mesalazinum inn - endaþarmsstíll - 500 mg
pentasa endaþarmsstíll 1 g
ferring lægemidler a/s - mesalazinum inn - endaþarmsstíll - 1 g
dolorin junior endaþarmsstíll 125 mg
williams & halls ehf.* - paracetamolum inn - endaþarmsstíll - 125 mg
paracet endaþarmsstíll 125 mg
karo pharma as - paracetamolum inn - endaþarmsstíll - 125 mg
asacol (mesalazine espl) endaþarmsstíll 1 g
tillotts pharma ab - mesalazinum inn - endaþarmsstíll - 1 g
paracet endaþarmsstíll 60 mg
karo pharma as - paracetamolum inn - endaþarmsstíll - 60 mg